Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Akari Hiramitsu
Institution:
National Cancer Center Hospital
Observed institution:
National Cancer Center Hospital
ORCID:
0009-0000-9741-7424
Observed ORCID:
0009-0000-9741-7424
OpenAlex ID:
A5093042005
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
·
Clinical Cancer Research
·
13
PDF
Supplementary Figure S6 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
PDF
Supplementary Figure S1 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Figure S5 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
PDF
Supplementary Figure S3 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S2 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S3 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S1 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Figure S4 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Figure S2 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Data from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S4 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Data from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Show more works
View as search
Works count:
13
Citation count:
13
H-index:
1
I10-index:
1
Year
Topic
Type